-
Persistent morbidity in Clade IIb mpox patients: interim results of a long-term follow-up study, Belgium, June to November 2022
-
View Affiliations Hide AffiliationsNicole Berens-Rihanberens itg.be
-
View Collaborators
Members of the ITM Monkeypox Study Group: Irith De Baetselier, Dorien Van den Bossche, Kevin K Ariën, Jasmine Coppens, Fien Vanroye, Kadrie Ramadan, Karin Van Looveren, Jolien Baeyens, Leo Heyndrickx, Hanne Rasson, Jacob Verschueren, Antonio Rezende, Leen Vandenhove, Bea VuylstekeView Citation Hide Citation
Citation style for this article: . Persistent morbidity in Clade IIb mpox patients: interim results of a long-term follow-up study, Belgium, June to November 2022. Euro Surveill. 2023;28(7):pii=2300072. https://doi.org/10.2807/1560-7917.ES.2023.28.7.2300072 Received: 02 Feb 2023; Accepted: 15 Feb 2023
Abstract
While mpox was well characterised during the 2022 global Clade IIb outbreak, little is known about persistent morbidity. We present interim results of a prospective cohort study of 95 mpox patients assessed 3–20 weeks post-symptom onset. Two-thirds of participants had residual morbidity, including 25 with persistent anorectal and 18 with genital symptoms. Loss of physical fitness, new-onset/worsened fatigue and mental health problems were reported in 36, 19 and 11 patients, respectively. These findings require attention by healthcare providers.
Full text loading...